Elizabeth Handorf

Associate Professor

Rutgers, The State Univ. of NJ

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Elizabeth Handorf serves as an Associate Professor at Rutgers, The State University of New Jersey, United States. Her research interests focus on cancer risk communication, health disparities, and clinical effectiveness, evidenced by her recent publications on topics such as digital interventions for skin cancer risk and the cost-effectiveness of genetic risk assessments. Additionally, she studies the comparative effectiveness of treatments for renal cell carcinoma and explores food insecurity in cancer patients.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (1)

carolyn heckman

Rutgers Cancer Institute of New Jersey

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Elizabeth Handorf

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Digital Skin Cancer Risk Reduction Interventions for Young Adults: Findings from a Hybrid Type-II Effectiveness-Implementation Trial

Cost-Effectiveness of Remote Tailored Risk Communication and Navigation for Hereditary Genetic Risk Assessment Uptake: Economic Evaluation From the Genetic Risk Assessment for Cancer Education and Empowerment Trial

Comparison of Outcomes Between African American and European American Patients With Metastatic Clear Cell Renal Cell Carcinoma Receiving Immune Checkpoint Inhibitors

Food Insecurity and Dietary Quality in African American Patients with Gastrointestinal Cancers: An Exploratory Study

A community-based cervical cancer education and navigation program for Korean American women.

SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Analysis of survival data with nonproportional hazards: A comparison of propensity‐score‐weighted methods

Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies

Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma

Collaborators (1)

carolyn heckman

Make your next move.